Condition: NSCLC Adenocarcinoma · Solid Tumor · Sponsor: Nerviano Medical Sciences (Shanghai) Ltd.
This is a multi-part, open-label, non-randomized phase Ib/II clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of atamparib, an investigational agent, in patients with advanced or metastatic non-small cell lung cancer (NSCLC) adenocarcinoma. The study comprises dose escalation (phase Ib) and expansion (phase II).
This description comes directly from the study's public registry record.
Olivia Chi Operations Program Lead, Master · 86 18621117100 · olivia.chi@nervianoms.com
Qin Kang, Senior Project manager, Tigermed, bachelor · 86 158 5828 6160 · qin.kang@tigermedgrp.com
Always discuss trial participation with your own doctor first.
| Unit 3.53, 3rd Floor, No. 5, Lane 720 Cailun Road, Pilot Free Trade Zone, Shanghai, P.R.China | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07374419